Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donald R Stanski

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Journal of Clinical Pharmacology|January 18, 2008
Communicating with the FDA: the "third rail" of a new model for drug developmentDonald R Stanski, John J Orloff
Clinical Pharmacology and Therapeutics|April 14, 2021
The Titration Paradox Turns Pharmacology Upside DownSteven L Shafer, Donald R Stanski
Journal of Pharmacokinetics and Pharmacodynamics|November 12, 2005
Getting the Dose Right: report from the Tenth European Federation of Pharmaceutical Sciences (EUFEPS) conference on optimizing drug developmentDonald R Stanski, Malcolm Rowland, Lewis B Sheiner
Lancet (London, England)|September 27, 2005
Inadequate anaesthesia in lethal injection for executionMark J S Heath, Donald R Stanski, Derrick J Pounder
Microbiology Spectrum|April 12, 2022
Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19Yuri Kosinsky, Kirill Peskov, Donald R Stanski, et al.
Physiological Reports|March 1, 2018
Individualized treatment strategies for hyperuricemia informed by a semi-mechanistic exposure-response model of uric acid dynamicsSergey Aksenov, Carl C Peck, Ulf G Eriksson, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 27, 2014
Translational pharmacokinetic modeling of fingolimod (FTY720) as a paradigm compound subject to sphingosine kinase-mediated phosphorylationNelleke Snelder, Bart A Ploeger, Olivier Luttringer, et al.
Respiratory Research|April 27, 2011
Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approachesDidier Renard, Michael Looby, Benjamin Kramer, et al.
Journal of Clinical Pharmacology|October 1, 2010
Fostering culture and optimizing organizational structure for implementing model-based drug developmentLiping Zhang, Sandra R Allerheiligen, Richard L Lalonde, et al.
Contemporary Clinical Trials|December 1, 2005
Enriched analgesic efficacy studies: an assessment by clinical trial simulationHendrikus J M Lemmens, D Russell Wada, Catherine Munera, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Journal of Clinical Pharmacology|January 18, 2008
Communicating with the FDA: the "third rail" of a new model for drug developmentDonald R Stanski, John J Orloff
Clinical Pharmacology and Therapeutics|April 14, 2021
The Titration Paradox Turns Pharmacology Upside DownSteven L Shafer, Donald R Stanski
Journal of Pharmacokinetics and Pharmacodynamics|November 12, 2005
Getting the Dose Right: report from the Tenth European Federation of Pharmaceutical Sciences (EUFEPS) conference on optimizing drug developmentDonald R Stanski, Malcolm Rowland, Lewis B Sheiner
Lancet (London, England)|September 27, 2005
Inadequate anaesthesia in lethal injection for executionMark J S Heath, Donald R Stanski, Derrick J Pounder
Microbiology Spectrum|April 12, 2022
Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19Yuri Kosinsky, Kirill Peskov, Donald R Stanski, et al.
Physiological Reports|March 1, 2018
Individualized treatment strategies for hyperuricemia informed by a semi-mechanistic exposure-response model of uric acid dynamicsSergey Aksenov, Carl C Peck, Ulf G Eriksson, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 27, 2014
Translational pharmacokinetic modeling of fingolimod (FTY720) as a paradigm compound subject to sphingosine kinase-mediated phosphorylationNelleke Snelder, Bart A Ploeger, Olivier Luttringer, et al.
Respiratory Research|April 27, 2011
Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approachesDidier Renard, Michael Looby, Benjamin Kramer, et al.
Journal of Clinical Pharmacology|October 1, 2010
Fostering culture and optimizing organizational structure for implementing model-based drug developmentLiping Zhang, Sandra R Allerheiligen, Richard L Lalonde, et al.
Contemporary Clinical Trials|December 1, 2005
Enriched analgesic efficacy studies: an assessment by clinical trial simulationHendrikus J M Lemmens, D Russell Wada, Catherine Munera, et al.
Pageof 2